Molecular Signaling group is interested in discovery and exploring cancer drug targets through molecular signal processing. Our overall goals are to identify and characterize pharmacologically new agonists and antagonists for the receptor and explore their potential for treating human cancer conditions. To reach this goal, we integrate both experimental and computational expertise within our research group.
Molecular communication and signaling
The MS group focuses on understanding the molecular signaling network communication. These networks play crucial roles in gene expression regulation and cell fate determination. By investigating molecular signaling pathways that contribute to cancer and other diseases. Improper intra and/or extracellular signal transduction affects cells well-being and lead to various diseases. Specifically, we study the canonical and non-canonical signaling pathways activated by receptors at single cell level. Our group deploys interdisciplinary research knowledge such as cell and molecular experimental approach, single cell imaging, image processing, signal processing, computational models and bioinformatics.
Preclinical research for health and medicine
We have been working on cancer preclinical studies to identify whether a drug is ready for clinical trials. We apply both “forward pharmacology” and “reverse pharmacology” approach. We screen broad range of new class of drug-like molecules using in vitro and in vivo experiments. We also perform in silico profiling using computer models of the drug–target interactions.